DFM Platform
DFM Funding Monitor

LIACFLASH: a life changing IOeRT technology for oncology carebroad

LIAC FLASH · Horizon Europe grant · 2022-12-01–2025-05-31

EC contribution

€2,499,962

Total cost

€3,571,375

Beneficiaries

1
About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →

Objective

Radiation Therapy is, along with surgery, the most effective therapeutic approach for the treatment of solid tumours. Unfortunately, biological effects of radiation dose to healthy organs at risk (often surrounding targeted tumour mass) represent a major dose-limiting constraint in Radiation Therapy. This implies that tumours cannot be always successfully treated, as delivered dose might not be enough for an effective treatment, decreasing survival of these cancer patients. LIACFLASH is an IOeRT system for cancer treatment built on a breakthrough scientific discovery: the FLASH effect, which enables delivery of high radiation dose with significantly reduced associated radiocytotoxicity, while achieving efficient tumour killing, widening the therapeutic window.

Beneficiaries (1)

OrganisationCountryRoleEC contributionSME
S.I.T. - SORDINA IORT TECHNOLOGIES SPA IT coordinator €2,499,962 Yes

Get the EU Defence Funding Calendar — free

The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.

We store your email to send the calendar and the weekly DFM Analysis briefing. Nothing else. Unsubscribe anytime.

Or browse all open defence & dual-use calls on the funding calendar →

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.

DFM Analysis, our free weekly newsletter, tracks the EU defence-funding programmes, calls and decisions behind this page. Subscribe free →